Wellbeing Checkup: Mobile Technology

Vamsidhar Velcheti, MD, speaks on Lung Cancer Health Equity SU2C Catalyst® Research Team (with support from Bristol Myers Squibb): The team will investigate whether mobile technology services can improve patient outcomes for underserved, underrepresented diverse patients. Specifically, the team will study whether Black, Hispanic and Asian non-small cell lung cancer (NSCLC) patients across NYC using the ApricityRx™ digital platform, as well as the on-demand ApricityRx™ Cancer Adverse event Rapid Evaluation (C.A.R.E.) service to see if their long-term outcomes can be improved and whether technology-enabled monitoring can close gaps in clinical care for underrepresented populations.